# US 2024/0199592 A1 · Chromene derivatives as inhibitors of tcr-nck interaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199592 A1
- Document ID: US20240199592A1
- Status: Published application
- Kind: A1
- Application number: 18/471,594
- Filed: 2023-09-21
- Published: 2024-06-20
- Earliest claimed: 2018-02-27
- Assignees: Artax Biopharma Inc.
- Applicants: Artax Biopharma Inc.
- Inventors: Julio Castro; Andres Gagete Mateos; Peter J. Machin; Christopher Loren Vandeusen
- Web page: https://patentgrep.com/patent/US20240199592A1

## CPC

- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is R, halogen, —CN, —OR, —NHR, or —N(R)2;
R2 is R, halogen, —C(O)N(R)2, or —N(R)2;
R3 is hydrogen or an electron withdrawing group;
each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 member saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
or two R on the same nitrogen are taken together with their intervening atoms to form an optionally substituted 5-6 membered heterocyclic ring having 0-1 heteroatoms in addition to the nitrogen attached thereto wherein such heteroatom is oxygen, nitrogen, or sulfur;
L1 is a covalent bond or a C1-4 bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —C(R)2—, —CH(R)—, —C(F)2—, —N(R)—, —C(O)N(R)—, —RNC(O)—, —OC(O)N(R)—, —N(R)C(O)N(R)—, or -Cy-;
L2 is a covalent bond or a C1-4 bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —C(R)2—, —CH(R)—, —C(F)2—, —N(R)—, —C(O)N(R)—, —RNC(O)—, —OC(O)N(R)—, or —N(R)C(O)N(R)—; and
each Cy is independently a bivalent optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, optionally substituted phenylene, an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
wherein said compound is other than a compound selected from:

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound is selected from any of formulae IV-a, IV-b, IV-c, or IV-d:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6)

The compound according to claim 6, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 5)

The compound according to claim 5, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 9)

The compound according to claim 9, wherein the compound formula is:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 2)

The compound of claim 2, wherein the compound formula is
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The compound of claim 12, wherein the compound formula is
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, adjuvant, or vehicle.

### Claim 15 (depends on 1)

A method of modulating a protein-protein interaction in a cell comprising contacting the cell with the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

### Claim at position 15

-19. (canceled)

### Claim 20 (depends on 1)

A method of modulating the protein-protein interaction between TCR-Nck in a biological sample comprising contacting the biological sample with the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

### Claim 21 (depends on 1)

A method of modulating the protein-protein interaction between TCR-Nck in a patient comprising administering to the patient the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

### Claim 22 (depends on 1)

A method of treating a TCR-Nck mediated disease, disorder, or condition in a patient in need thereof, comprising administering to the patient the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

### Claim 23 (depends on 1)

A method of treating a disease, disorder, or condition in a patient in need thereof, comprising administering to the patient the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, wherein the disease, disorder, or condition is selected from rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications from diabetes, multiple sclerosis, systemic lupus erythematosus, cutaneous lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, autoimmune hepatitis, myansthenia gravis, ankylosing spondylitis, Crohn's disease, leukemias, lymphomas, and thromboembolic and allergic complications associated with leukemias and lymphomas.

### Claim 24 (depends on 22)

The method according to claim 22, further comprising administering an additional therapeutic agent in combination with said compound.

### Claim 25

A compound of Formula VIII:
or a pharmaceutically acceptable salt thereof, wherein:
R2 is R, halogen, —C(O)N(R)2, or —N(R)2;
R3 is hydrogen or an electron withdrawing group;
each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 member saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
or two R on the same nitrogen are taken together with their intervening atoms to form an optionally substituted 5-6 membered heterocyclic ring having 0-1 heteroatoms in addition to the nitrogen attached thereto wherein such heteroatom is oxygen, nitrogen, or sulfur;
L1 is a covalent bond or a C1-4 bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —C(R)2—, —CH(R)—, —C(F)2—, —N(R)—, —C(O)N(R)—, —RNC(O)—, —OC(O)N(R)—, —N(R)C(O)N(R)—, or -Cy-;
L2 is a covalent bond or a C1-4 bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —C(R)2—, —CH(R)—, —C(F)2—, —N(R)—, —C(O)N(R)—, —RNC(O)—, —OC(O)N(R)—, or —N(R)C(O)N(R)—; and
each Cy is independently a bivalent optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, optionally substituted phenylene, an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 26 (depends on 25)

The compound according to claim 25, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
